

CURRICULUM VITAE

Prof. Dr. NECDET ÜSKENT, MD

I. PRESENT ACADEMIC RANK AND POSITION

2006-Present Professor of Internal Medicine
 Professor of Medical Oncology
 Professor of Hematology

Anadolu Medical Center (affiliated with John's Hopkins University)
Institute of Oncology

II. EDUCATION

University : University of Ankara School of Medicine, 1971

Residency : GATA, Internal Medicine, 1975-1979

Fellowship : University of Texas, Hematology & Oncology, 1979-1982

Other : University of London Charing Cross Hospital-UK,
Bone Marrow Transplantation, 1986 April-October (6
months)

University of Basel, Kantonsspital Basel-Switzerland
Loco-regional Chemotherapy, 1989 September-January (3
months)

University of London, Royal Free Hospital
Stem Cell Transplantation, 1998

III. BOARD CERTIFICATION

Internal Medicine, 1979
Medical Oncology, 1983
Hematology, 1983

IV. MEDICAL LICENSURE

Texas license - licence number: G 1791
Georgia licence – licence number: 22971
ESMO Medical oncology certificate – certificate number: 258-495-1

V. PREVIOUS PROFESSIONAL POSITIONS AND APPOINTMENTS

1982-1984 Medicine	Assistant Professor of Internal Medicine, GATA Department of Internal Medicine
1984-1989 Medicine,	Associate Professor of Internal Medicine, GATA Department of Internal Medicine, Division of Medical Oncology
1989-2001 Director)	Professor of Internal Medicine, GATA Department of Internal Medicine (Chief of Hematology &Oncology Department
2001-2006	Professor of Internal Medicine, Kadir Has Univeersity School of Medicine Chief of Internal Medicine Department

VI. EDUCATION—TEACHING

1987-1990	Medical School : GATA School of Medicine: Classes 3 , 4 and 6, 1984-2001 University of Marmara School of Medicine: Classes 3 and 4,
2006	Kadir Has University, School of Medicine: Classes 3 and 4, 2001-
	Graduate School : İstanbul University Çapa Institute of Oncology Courses for Doctorate Students, 1990-1992
	Continuing Education : ESMO Courses in Antalya, İstanbul, and Ankara Medical Oncology Courses in National Cancer Congresses New Trends in Oncology-İstanbul, 2008 and 2009

VII. EDUCATION—JOURNALS

Member of Editorial Board and Reviewer of

- Journal of Hematology and Oncology (Turkey),
- Cancer (Turkey),
- Journal of Oncology (Turkey),
- New Drugs (International)

VIII. PROFESSIONAL AND SOCIETY MEMBERSHIPS

ASCO (American Society of Clinical Oncology)

ESMO (European Society of Medical Oncology)

National Society of Medical Oncology

Turkish Association of Hematology

IX. INVITED VISITING PROFESSORSHIPS

University of London, Charing Cross and Westminster Medical School, 1986

University of London Royal Free Hospital, 1998

X. PRESENTATIONS AT NATIONAL MEETINGS

More than 200 Oral Presentations in National Meetings*

XI. PRESENTATIONS AT INTERNATIONAL MEETINGS

More than 100 abstracts and oral presentations in International Congresses *

XII. INTRAMURAL PRESENTATIONS

Oncology Board, Grand Rounds and Journal Clubs weekly

XIII. CLINICAL PRACTICE, INTERESTS, AND ACCOMPLISHMENTS

Breast cancer, Lung cancer, Gastrointestinal Cancers, Lymphoma,
Melanoma, Myeloma, Cancer Vaccines and Targeted therapies

XIV. RESEARCH INTERESTS

Cancer Vaccines and Gene Therapies

International Multi-National Multicentric and National Multicentric Phase 3 Studies:

1. ISEL Study: Gefitinib in Placebo randomised double blind phase III study in Previously Treated Resistant or Progressive Non-Small Cell Lung Cancer, 2004
2. Efficacy of Docataxel as a First Line Single Agent Compare to Docataxel+ Cisplatin in Stage III/IV Non-Small Cell Lung Cancer, Phase III, Randomised Study, 2000
3. Florourasil+ Leucovorine vs Florourasil+ alpha Inteferon in metastatic Colorectal cancer, Phase III, Randomised Study, 1999
4. Neoadjuvant FOLFIRI vs FOLFOX in the resectability of liver metastases in colo-rectal cancer, Randomized National Multicentric Study
5. Anastrozol Farmacovijilans Study in Early Postmenapausal Breast Cancer Patients, in Turkey. Multicentric National Study (Coordinator), 2008
6. Interferon Maintenance in Multiple Myeloma patients in plato phase, multinational, multicentric study, 1997
7. A Phase III Clinical Trial to Evaluate the safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7. Compared to Dacarbazine(DTIC) or Temozolamide (TMZ) in Subjects with Recurren Metastatic Melanoma Randomized 2010

XV. BIBLIOGRAPHY

More than 200 published articles in National and Internatinal Journals*

* List of details can be shared upon the request.